BACKGROUND AND OBJECTIVES: The aim of this study was to evaluate a new fluorescently labeled chimeric anti-CEA antibody for improved detection and resection of colon cancer. METHODS: Frozen tumor and normal human tissue samples were stained with chimeric and mouse antibody-fluorophore conjugates for comparison. Mice with patient-derived orthotopic xenografts (PDOX) of colon cancer underwent fluorescence-guided surgery (FGS) or bright-light surgery (BLS) 24 hr after tail vein injection of fluorophore-conjugated chimeric anti-CEA antibody. Resection completeness was assessed using postoperative images. Mice were followed for 6 months for recurrence. RESULTS: The fluorophore conjugation efficiency (dye/mole ratio) improved from 3-4 to >5.5 with the chimeric CEA antibody compared to mouse anti-CEA antibody. CEA-expressing tumors labeled with chimeric CEA antibody provided a brighter fluorescence signal on frozen human tumor tissues (P = 0.046) and demonstrated consistently lower fluorescence signals in normal human tissues compared to mouse antibody. Chimeric CEA antibody accurately labeled PDOX colon cancer in nude mice, enabling improved detection of tumor margins for more effective FGS. The R0 resection rate increased from 86% to 96% with FGS compared to BLS. CONCLUSION: Improved conjugating efficiency and labeling with chimeric fluorophore-conjugated antibody resulted in better detection and resection of human colon cancer in an orthotopic mouse model.
BACKGROUND AND OBJECTIVES: The aim of this study was to evaluate a new fluorescently labeled chimeric anti-CEA antibody for improved detection and resection of colon cancer. METHODS: Frozen tumor and normal human tissue samples were stained with chimeric and mouse antibody-fluorophore conjugates for comparison. Mice with patient-derived orthotopic xenografts (PDOX) of colon cancer underwent fluorescence-guided surgery (FGS) or bright-light surgery (BLS) 24 hr after tail vein injection of fluorophore-conjugated chimeric anti-CEA antibody. Resection completeness was assessed using postoperative images. Mice were followed for 6 months for recurrence. RESULTS: The fluorophore conjugation efficiency (dye/mole ratio) improved from 3-4 to >5.5 with the chimeric CEA antibody compared to mouse anti-CEA antibody. CEA-expressing tumors labeled with chimeric CEA antibody provided a brighter fluorescence signal on frozen humantumor tissues (P = 0.046) and demonstrated consistently lower fluorescence signals in normal human tissues compared to mouse antibody. Chimeric CEA antibody accurately labeled PDOX colon cancer in nude mice, enabling improved detection of tumor margins for more effective FGS. The R0 resection rate increased from 86% to 96% with FGS compared to BLS. CONCLUSION: Improved conjugating efficiency and labeling with chimeric fluorophore-conjugated antibody resulted in better detection and resection of humancolon cancer in an orthotopic mouse model.
Authors: Skye C Mayo; Carlo Pulitano; Hugo Marques; Jorge Lamelas; Christopher L Wolfgang; Wassila de Saussure; Michael A Choti; Isabelle Gindrat; Luca Aldrighetti; Eduardo Barrosso; Gilles Mentha; Timothy M Pawlik Journal: J Am Coll Surg Date: 2013-02-21 Impact factor: 6.113
Authors: Hop S Tran Cao; Sharmeela Kaushal; Cristina A Metildi; Rhiana S Menen; Claudia Lee; Cynthia S Snyder; Karen Messer; Minya Pu; George A Luiken; Mark A Talamini; Robert M Hoffman; Michael Bouvet Journal: Hepatogastroenterology Date: 2012-09
Authors: Süleyman Yedibela; Peter Klein; Karsta Feuchter; Martin Hoffmann; Thomas Meyer; Thomas Papadopoulos; Jonas Göhl; Werner Hohenberger Journal: Ann Surg Oncol Date: 2006-09-29 Impact factor: 5.344
Authors: Kei Kawaguchi; Qinghong Han; Shukuan Li; Yuying Tan; Kentaro Igarashi; Tasuku Kiyuna; Kentaro Miyake; Masuyo Miyake; Bartosz Chmielowski; Scott D Nelson; Tara A Russell; Sarah M Dry; Yunfeng Li; Arun S Singh; Mark A Eckardt; Michiaki Unno; Fritz C Eilber; Robert M Hoffman Journal: Cell Cycle Date: 2018-03-19 Impact factor: 4.534
Authors: Cristina A Metildi; Sharmeela Kaushal; George A Luiken; Robert M Hoffman; Michael Bouvet Journal: J Am Coll Surg Date: 2014-03-02 Impact factor: 6.113
Authors: Kei Kawaguchi; Kentaro Igarashi; Takashi Murakami; Tasuku Kiyuna; Scott D Nelson; Sarah M Dry; Yunfeng Li; Tara A Russell; Arun S Singh; Bartosz Chmielowski; Michiaki Unno; Fritz C Eilber; Robert M Hoffman Journal: Cell Cycle Date: 2017-04-20 Impact factor: 4.534
Authors: Yukihiko Hiroshima; Thinzar M Lwin; Takashi Murakami; Ali A Mawy; Tanaka Kuniya; Takashi Chishima; Itaru Endo; Bryan M Clary; Robert M Hoffman; Michael Bouvet Journal: J Surg Oncol Date: 2016-10-03 Impact factor: 3.454
Authors: Kentaro Igarashi; Kei Kawaguchi; Tasuku Kiyuna; Kentaro Miyake; Masuyo Miyake; Shukuan Li; Qinghong Han; Yuying Tan; Ming Zhao; Yunfeng Li; Scott D Nelson; Sarah M Dry; Arun S Singh; Irmina A Elliott; Tara A Russell; Mark A Eckardt; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Hiroyuki Tsuchiya; Fritz C Eilber; Robert M Hoffman Journal: Cell Cycle Date: 2018-04-10 Impact factor: 4.534
Authors: Cristina A Metildi; Csilla N Felsen; Elamprakash N Savariar; Quyen T Nguyen; Sharmeela Kaushal; Robert M Hoffman; Roger Y Tsien; Michael Bouvet Journal: Ann Surg Oncol Date: 2014-10-16 Impact factor: 5.344